Clinical Trials Browser

Phase 2 × Unknown × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all

NCT04888741 2023-09-28

MoTD

Phase 2 Unknown

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04709731 2021-02-03

CarPAs

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04578847 2020-10-08

READIT

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02268370 2019-11-29

TRAD

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04043676 2019-08-02

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02889003 2018-03-22

PIO2STOP

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03241199 2017-08-08

The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03205267 2017-07-02

BODO

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01690065 2016-05-11

NICE-BORA

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT02422719 2016-05-11

REVITAL

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02687425 2016-02-22

SESPI

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01802450 2015-09-17

DASAPOST

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02511340 2015-07-30

A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00008307 2014-01-06

Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders

Phase 2 Unknown

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Congenital Abnormalities, Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Recurrence, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating, Intraocular Lymphoma

NCT01503502 2013-04-10

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01221376 2013-03-26

Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01513603 2012-01-20

Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia

Phase 2 Unknown

LymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01227135 2011-11-30

Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00112775 2011-06-07

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00598624 2009-08-11

AlloTreo

Phase 2 Unknown

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lymphoma, Large B-Cell, Diffuse

NCT00146913 2007-04-27

AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year

Phase 2 Unknown

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive